— Human Acellular Vessels™ (HAVs™) shipped to six hospitals in Ukraine for treatment of civilian and military vascular trauma injuries —
— Strengthened leadership team with appointment of Shamik Parikh M.D., as Chief Medical Officer —
— Multiple scientific meeting presentations and publications highlighting clinical and preclinical HAV data —
— Conference call and live webcast at 8:00 a.m. ET today —
DURHAM, N.C., May 13, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues, complex tissue systems, and organs at commercial scale, today announced financial results for the first quarter ended March 31, 2022, and highlighted recent corporate accomplishments.
“We are pleased by the progress Humacyte has made in the first quarter of 2022 as we continue to advance our universally implantable, bioengineered human tissue platform. We believe our lead candidate, the HAV, is uniquely suited for scenarios in which the current standard of care is unavailable or inadequate. During the humanitarian crisis in Ukraine, we are proud to be able to provide HAVs to front-line hospitals for the treatment of military and civilian vascular trauma injuries.” said Laura Niklason, M.D., Ph.D., Founder, President and Chief Executive Officer of Humacyte. “In addition, we were pleased to welcome Dr. Shamik Parikh as our Chief Medical Officer. Dr. Parikh joins us at a pivotal time, as we look forward to the planned completion of our late-stage clinical trials in vascular trauma and arteriovenous access for hemodialysis and, if approved, work to bring the HAV to market in its initial indications.”
First Quarter 2022 and Recent Corporate Highlights
Clinical Updates
Corporate Updates
First Quarter 2022 Financial Highlights
Conference Call and Webcast Details
Date: | Friday, May 13, 2022 |
Time: | 8:00 a.m. ET |
Conference Call Details: | Toll-Free: 1-877-704-4453 International: 1-201-389-0920 Conference ID: 13729522 |
Webcast: | Webcast Link – Click Here |
A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the investors section of the Company’s website for at least 30 days.
About Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and complex tissue and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm HAV for arteriovenous (AV) access for performing hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation, and has also received FDA Fast Track designation. The HAV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. The HAV is an investigational product and has not been approved for sale by the FDA or any international regulatory agency. For more information, visit www.Humacyte.com.
Forward-Looking Statements
This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements regarding the Company’s cash runway, the initiation, timing, progress, and results of our preclinical and clinical trials; the anticipated characteristics and performance of our HAVs; our ability to successfully complete, preclinical and clinical trials for our HAVs; the anticipated benefits of our HAVs relative to existing alternatives; the anticipated commercialization of our HAVs and our ability to manufacture at commercial scale; the implementation of our business model and strategic plans for our business; our rights and obligations under our partnership with Fresenius Medical Care; the scope of protection we are able to establish and maintain for intellectual property rights covering our HAVs and related technology; the timing or likelihood of regulatory filings and approvals; timing, scope, and rate of reimbursement for our HAVs; our expectations regarding our initiative to provide HAVs to Ukraine; and our estimated available market opportunity. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, the impact of COVID-19 on Humacyte’s business, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, and/or competitive factors, and other risks and uncertainties, including those included under the header “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021, filed by Humacyte with the SEC and in subsequent SEC filings. Most of these factors are outside of Humacyte’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com
Humacyte Media Contact:
Heather Anderson
6 Degrees
919-827-5539
handerson@6degreespr.com
media@humacyte.com
Humacyte, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(unaudited)
(in thousands except for share and per share amounts)
Three Months Ended March 31, |
|||||||
2022 | 2021 | ||||||
Grant Revenue | $ | 233 | $ | 155 | |||
Operating expenses: | |||||||
Research and development | 16,314 | 15,137 | |||||
General and administrative | 5,682 | 4,787 | |||||
Total operating expenses | 21,996 | 19,924 | |||||
Loss from operations | (21,763 | ) | (19,769 | ) | |||
Other income (expenses), net | |||||||
Change in fair value of contingent earnout liability | 3,258 | — | |||||
Other expenses (net) | (1,327 | ) | (532 | ) | |||
Total other income (expenses), net | 1,931 | (532 | ) | ||||
Net loss and comprehensive loss | $ | (19,832 | ) | $ | (20,301 | ) | |
Net loss per share, basic and diluted | $ | (0.19 | ) | $ | (3.46 | ) | |
Weighted-average shares outstanding, basic and diluted | 103,004,088 | 5,874,700 | |||||
Humacyte, Inc.
Condensed Consolidated Balance Sheets
(unaudited)
(in thousands)
March 31, 2022 |
December 31, 2021 |
||||||
Assets | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 198,222 | $ | 217,502 | |||
Short-term investments | 8,000 | 8,000 | |||||
Prepaid expenses and other current assets | 3,073 | 3,838 | |||||
Total current assets | 209,295 | 229,340 | |||||
Property, plant and equipment, net | 33,540 | 35,034 | |||||
Lease right-of-use assets, net | 21,633 | 22,159 | |||||
Total assets | $ | 264,468 | $ | 286,533 | |||
Liabilities and Stockholders’ Equity | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 3,037 | $ | 2,094 | |||
Accrued expenses | 5,460 | 6,757 | |||||
Other current liabilities | 2,266 | 2,199 | |||||
Total current liabilities | 10,763 | 11,050 | |||||
Contingent earnout liability | 100,402 | 103,660 | |||||
Finance lease obligation, net of current portion | 20,581 | 21,109 | |||||
SVB loan payable | 27,739 | 27,361 | |||||
Other long-term liabilities | 1,093 | 1,179 | |||||
Total liabilities | 160,578 | 164,359 | |||||
Stockholders’ equity | |||||||
Common stock and additional paid-in capital | 538,295 | 536,747 | |||||
Accumulated deficit | (434,405 | ) | (414,573 | ) | |||
Total stockholders’ equity | 103,890 | 122,174 | |||||
Total liabilities and stockholders’ equity | $ | 264,468 | $ | 286,533 |
FORT WORTH, Texas, Dec. 24, 2024 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL) today announced…
- Proprietary data and samples from TRACERx and Achilles’ Material Acquisition Platform (MAP) will be…
If you are male and in your 40's and 50's and feel your testosterone levels…
Transforming Anxiety into Positive Energy: A New Approach by The Anxiety ClinicBondi Junction, New South…
Embracing Mental Well-Being During the Festive SeasonCarlton North, Australia--(Newsfile Corp. - December 24, 2024) -…
If you are researching the strongest over the counter weight loss supplements in 2025 -…